About Boltz
Boltz PBC is a public-benefit AI research company that builds open-source biomolecular AI models and software platforms for drug discovery, serving pharmaceutical and biotech companies. Its flagship products—including Boltz-1, Boltz-2, BoltzGen, and the Boltz Lab hosted platform—enable scientists to predict biomolecular structures, estimate binding affinity, and design small molecules and proteins. The company's models are used by over 100,000 scientists across every top-20 pharma company and thousands of biotechs.
Company details
Funding
Total raised
$28M
Last stage
Seed
Investors
Founders
Gabriele Corso
MIT CSAIL researcher and lead architect of the Boltz biomolecular AI models, including Boltz-1 and Boltz-2.
LinkedInJeremy Wohlwend
MIT researcher and co-developer of the Boltz open-source biomolecular AI model series.
Saro Passaro
MIT researcher and co-developer of the Boltz open-source biomolecular AI model series.
Corso
Co-founder of Boltz PBC, leading the company as CEO. Previously involved in developing prolific technology for AI in biology turned into an open science business.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.